Intrahepatic cholangiocarcinoma (iCCA), the second most common primary liver cancer after hepatocellular carcinoma, remains one of the most challenging malignancies to treat due to its highly concealed and heterogeneous nature. A collaborative team from BGI Genomics and Zhongshan Hospital of Fudan University has now charted the molecular “chaos” of iCCA, providing a navigational framework for more precise diagnosis and treatment.. The research is published in Cell Reports Medicine.

The Keck School of Medicine of USC and the USC Viterbi School of Engineering have announced that the Alfred E. Mann Department of Biomedical Engineering will become a joint department between the two schools, forging a formal partnership in education, research and innovation in technology and medicine. This joint department, one of the first of its kind in California, builds on decades of cross-disciplinary research and breakthroughs at USC, including the world’s first FDA-approved artificial retina, the first brain implant to restore lost memory function, and innovations in immunotherapy to treat cancer. With added support from USC’s president and provost, the newly integrated biomedical engineering department will create new structures and gain new resources dedicated to further accelerating biomedical innovation, enriching educational programs and advancing technology in medicine. It will combine expertise in priority areas spanning medical devices, neuroengineering, imaging science, drug discovery, artificial intelligence (AI) and informatics, cellular and molecular bioengineering, and more. Facilities at both the Viterbi School of Engineering and the Keck School of Medicine will be devoted to the joint department, with the chair reporting to both deans. Yingxiao (Peter) Wang, PhD, the department’s current chair, who also holds the Dwight C. and Hildagarde E. Baum Chair in Biomedical Engineering, will help implement the transition by leading the department into its next phase.